Table 1.
Clinicopathologic characteristics in pituitary adenomas.
| Variables | No. | DNMT1 | DNMT3A | DNMT3B | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| + | − | P | + | − | P | + | − | P | ||
| Total | 63 | 21 | 42 | 23 | 40 | 20 | 43 | |||
| Gender | 0.72 | 0.41 | 0.33 | |||||||
| Female | 34 | 12 | 22 | 14 | 20 | 9 | 25 | |||
| Male | 29 | 9 | 20 | 9 | 20 | 11 | 18 | |||
| Mean age (yrs) ±SD | 47±16 | 47±16 | 47±16 | 0.95 | 45±15 | 48±17 | 0.55 | 49±14 | 46±17 | 0.52 |
| Tumor type | 0.22 | 0.68 | 0.59 | |||||||
| GH (acromegaly) | 24 | 6 | 18 | 6 | 18 | 9 | 15 | |||
| GH/PRL (acromegaly) | 2 | 0 | 2 | 1 | 1 | 0 | 2 | |||
| PRL (prolactinoma) | 10 | 2 | 8 | 5 | 5 | 5 | 5 | |||
| TSH | 2 | 2 | 0 | 1 | 1 | 0 | 2 | |||
| ACTH (Cushing) | 4 | 1 | 3 | 1 | 3 | 0 | 4 | |||
| ACTH (silent) | 5 | 3 | 2 | 3 | 2 | 2 | 3 | |||
| FSH/LH (NF) | 12 | 5 | 7 | 4 | 8 | 3 | 9 | |||
| Null cell (NF) | 1 | 1 | 0 | 1 | 0 | 0 | 1 | |||
| Silent subtype 3 | 3 | 1 | 2 | 1 | 2 | 1 | 2 | |||
| Tumor size | 0.02 | 0.08 | 0.38 | |||||||
| Micro-adenoma | 9 | 0 | 9 | 1 | 8 | 4 | 5 | |||
| Macro-adenoma | 54 | 21 | 33 | 22 | 32 | 16 | 38 | |||
| Invasion | 0.03 | 0.03 | 0.42 | |||||||
| Non-invasive | 30 | 6 | 24 | 7 | 23 | 8 | 22 | |||
| Invasive | 33 | 15 | 18 | 16 | 17 | 12 | 21 | |||
| Grade | ||||||||||
| I | 9 | 0 | 9 | 1 | 8 | 4 | 5 | |||
| II | 21 | 6 | 15 | 0.07 | 6 | 15 | 0.30 | 4 | 17 | 0.14 |
| III | 25 | 9 | 16 | 0.03 | 11 | 14 | 0.07 | 10 | 15 | 0.81 |
| IV | 8 | 6 | 2 | 0.001 | 5 | 3 | 0.02 | 2 | 6 | 0.40 |
ACTH – corticotroph adenoma; ACTHs – silent corticotroph adenoma; FSH/LH – gonadotroph adenoma; GH – somatotroph adenoma; GH/PRL – mammosomatotroph adenoma; PRL – lactotroph adenoma; Null cell – null cell adenoma; TSH – TSH cell adenoma; Silent subtype 3 – silent subtype 3 adenoma; M – methylated; UM – unmethylated; SD – standard deviation. The chi-square test was used to analyze the differences in frequencies of DNMTs immunoreaction and promoter methylation of TSGs among each group of pituitary adenomas.